Anika Therapeutics (ANIK) Misses Q4 EPS by 10c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.95 +0.38%
EPS Growth %: -125.0%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
PMCB, PLCE, DOMO, More
EPS Growth %: -125.0%
Financial Fact:
Interest income (expense), net: 93K
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of ($0.34), $0.10 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $39.62 million versus the consensus estimate of $37.71 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic jumps on earnings beat and raised guidance
- Humana reaffirms 2026 earnings guidance ahead of investor meetings
- Yext, Inc. (YEXT) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
